Boston Scientific Corp. <BSX.N>: Oppenheimer Cuts Target Price to $65 From $85
BSX•Related News
New Era Energy & Digital Secures 20-Year, 207 MW Ppa With Vistra
NUAI•
PTL switches auditor to Privatco after FundCertify resignation
PTLE•
Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
TLSA•
Merck's Keytruda Qlex Approved In Japan For Subcutaneous Administration For All Keytruda Indications Approved In Japan
MRK•
Brunswick names Aine Denari CEO effective Jan. 1, 2027 as David Foulkes retires
BC•